In support of these findings, in vitro experiments show that KITLG-activated mast cells demonstrate reduced proliferation and migration, suggesting that KITLG/KIT signaling may inhibit CRC progression and confirming its computational significance. The gene discussed is KITLG; the disease is colorectal carcinoma.